Boston Scientific Corporation (BSX) keeps impressing both investors and financial analysts. RBC Capital and Oppenheimer continue to maintain a bullish stance on the company, increasing price targets to $125 and $118 respectively. Leerink Partners also express confidence in the company maintaining their outperform recommendation. The company reported better than forecast earnings for Q2 2025, raising their yearly view, which led to share price increments, with BSX shares being sought after by Avior Wealth Management and GC Wealth Management. The acquisition of BioEnvelope Business for $88M indicates an ambitious expansion into the breast reconstruction market.
However, the stock has seen some volatility, performing slightly poorer than the general market. This comes amidst a change in executive leadership for Peripheral Interventions, marking a new era for the company. Notwithstanding, analysts like Barclays and Canaccord Genuity remain bullish, increasing their price targets based on innovative IVL market opportunities, efficacious Robotics, and Devices performing excellently.
The firm will be having its 2025 Investor day, with important focus on Q3 2025 results. BSX's balance sheet remains healthy amidst strong growth forecasts for their MedSurg portfolio.
Boston Scientific Corp BSX News Analytics from Thu, 23 Jan 2025 08:00:00 GMT to Fri, 03 Oct 2025 20:08:23 GMT - Rating 7 - Innovation 6 - Information 8 - Rumor -3
